A Phase 2 interventional study of pemetrexed and gemcitabine in Lung Neoplasms, sponsored by Eli Lilly and Company. Terminated at 17 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2010-08-17.
Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 71 studies testing pemetrexed in Lung Neoplasms — 6 open to participants now, 10 under way, 4 of them phase 3. Pemetrexed · Lung Neoplasms.
Among the 71 studies testing pemetrexed in Lung Neoplasms, this one is the 43rd largest by enrollment of the 69 interventional ones that give a count, is one of 13 that started in 2006, is one of 47 in phase 2, and was the 23rd registered.
5,424 studies on the registry are indexed under Lung Neoplasms; 1,345 are open to participants now.
Browse Lung Neoplasms studies →6 of the 71 studies testing pemetrexed in Lung Neoplasms are open now, in 12 countries. Recruiting first, the newest first:
Shanghai Chest Hospital · Sites in China
Ages 18+
National Cancer Institute (NCI) · Sites in United States
Ages 70+
Fox Chase Cancer Center · Sites in United States
Ages 18+
Rutgers, The State University of New Jersey · Sites in United States
Ages 18+
AstraZeneca · Sites in United States, Belgium, Canada and 9 more countries
Ages 18–95
By country, each count listing its studies:
Pemetrexed: first FDA approval 2004 (ALIMTA), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →
Of the 995 Lung Neoplasms studies recruiting now, 682 (69%) set no upper age limit and 142 (14%) stop at 75 or younger; 45 take children under 18; 142 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
71 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 53 · Phase 3 11 · Phase 4 1
First in 2001; this study’s year is marked. 13 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 41 is below the median of 60 across 3,657 interventional studies indexed under Lung Neoplasms.
Median enrollment 48 across the 69 interventional studies. Of the 55 that completed or were terminated, 33 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 71 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
24 studies in Lung Neoplasms by Eli Lilly and Company: 2 open now, 6 under way, 1 of them phase 3. Of 16 finished, 11 (69%) have results posted.
Among the 24 studies in Lung Neoplasms by Eli Lilly and Company, this one is the 14th largest by enrollment of the 20 interventional ones that give a count, is one of 2 that started in 2006, is one of 14 in phase 2, and was the 7th registered.
Eli Lilly and Company’s Lung Neoplasms studies by the year they started, since 2002.
2 of the studies testing pemetrexed in Lung Neoplasms that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03793179Phase 3National Cancer Institute (NCI)Testing the Timing of Pembrolizumab Alone or With Chemotherapy as First Line Treatment and Maintenance in Non-small Cell Lung Cancer | 2027-09-30 |
| NCT05358548Rutgers, The State University of New JerseyATATcH Alternating Treatment Plans for Advanced Cancer | 2027-05-01 |
Add all 2 to your calendar (.ics) → With an account.
Among the 71 studies testing pemetrexed in Lung Neoplasms, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Eli Lilly and Company’s 24 in Lung Neoplasms:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to help answer:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Disease relapse at less than one year after neoadjuvant/adjuvant chemotherapy
Drug: pemetrexed · Drug: gemcitabine
Disease relapse at less than one year after neoadjuvant/adjuvant chemotherapy
Drug: Pemetrexed
Disease relapse at one year or greater after neoadjuvant/adjuvant chemotherapy
Drug: carboplatin · Drug: Pemetrexed
Disease relapse at one year or greater after neoadjuvant/adjuvant chemotherapy
Drug: pemetrexed · Drug: gemcitabine
500 mg/m2, intravenous (IV), every 14 days x 6 cycles or until disease progression
Also known as: LY231514, Alimta
1500 mg/m2, intravenous (IV), every 14 days x 6 cycles or until disease progression
Also known as: LY188011, Gemzar
area under the curve (AUC) 5, intravenous (IV), every 21 days x 6 cycles or until disease progression
500 mg/m2, intravenous (IV), every 21 days x 6 cycles or until disease progression
Also known as: LY231514, Alimta
Objective Tumor Response
Best response recorded from the start of treatment until disease progression/recurrence using Response Evaluation Criteria In Solid Tumors (RECIST) criteria. Complete Response=disappearance of all target lesions; Partial Response=30% decrease in sum of longest diameter of target lesions; Progressive Disease=20% increase in sum of longest diameter of target lesions; Stable Disease=small changes that do not meet above criteria.
Time frame: baseline to time of response (up to 17.5 months)
Overall Survival
Overall survival is the number of participants who were alive when the trial was terminated.
Time frame: baseline to trial termination (17.5 months)
Time to Progressive Disease
Time frame: baseline to measured progressive disease (up to 17.5 months)
Duration of Response
Time frame: time of response to progressive disease (up to 17.5 months)
Time to Treatment Failure
Time frame: baseline to stopping treatment (up to 17.5 months)
| Milestone | Less Than One Year: Pemetrexed | Less Than One Year: Pemetrexed + Gemcitabine | One Year or Greater: Pemetrexed + Carboplatin | One Year or Greater: Pemetrexed + Gemcitabine |
|---|---|---|---|---|
| Started | 14 | 11 | 7 | 9 |
| Completed | 0 | 0 | 0 | 0 |
| Not completed | 14 | 11 | 7 | 9 |
| Withdrew: Progressive disease | 8 | 5 | 4 | 2 |
| Withdrew: Adverse event | 1 | 3 | 1 | 1 |
| Withdrew: Lost to follow-up | 1 | 0 | 0 | 0 |
| Withdrew: Physician decision | 2 | 2 | 2 | 1 |
| Withdrew: Protocol entry criteria not met | 1 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 1 | 1 | 0 | 3 |
| Withdrew: Death | 0 | 0 | 0 | 1 |
| Withdrew: Sponsor decision | 0 | 0 | 0 | 1 |
Best response recorded from the start of treatment until disease progression/recurrence using Response Evaluation Criteria In Solid Tumors (RECIST) criteria. Complete Response=disappearance of all target lesions; Partial Response=30% decrease in sum of longest diameter of target lesions; Progressive Disease=20% increase in sum of longest diameter of target lesions; Stable Disease=small changes that do not meet above criteria.
| participants | Less Than One Year: Pemetrexed | Less Than One Year: Pemetrexed + Gemcitabine | One Year or Greater: Pemetrexed + Carboplatin | One Year or Greater: Pemetrexed + Gemcitabine |
|---|---|---|---|---|
| Complete Response | 0 | 0 | 0 | 0 |
| Partial Response | 7 | 0 | 2 | 1 |
| Stable Disease | 3 | 9 | 5 | 6 |
| Progressive Disease | 2 | 2 | 0 | 1 |
| Unknown | 2 | 0 | 0 | 1 |
Overall survival is the number of participants who were alive when the trial was terminated.
| participants alive | Less Than One Year: Pemetrexed | Less Than One Year: Pemetrexed + Gemcitabine | One Year or Greater: Pemetrexed + Carboplatin | One Year or Greater: Pemetrexed + Gemcitabine |
|---|---|---|---|---|
| Overall Survival | 6 (1.64 to 16.10) | 4 (0.99 to 11.66) | 6 (4.40 to 17.58) | 7 (0.16 to 14.78) |
No measurements were reported for this outcome.
No measurements were reported for this outcome.
No measurements were reported for this outcome.
Non-serious events are listed at a 1% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Less Than One Year: Pemetrexed | — | 3/14 (21.4%) | 14/14 (100%) |
| Less Than One Year: Pemetrexed + Gemcitabine | — | 5/11 (45.5%) | 11/11 (100%) |
| One Year or Greater: Pemetrexed + Carboplatin | — | 0/7 (0%) | 7/7 (100%) |
| One Year or Greater: Pemetrexed + Gemcitabine | — | 2/9 (22.2%) | 9/9 (100%) |
| Event | Less Than One Year: Pemetrexed | Less Than One Year: Pemetrexed + Gemcitabine | One Year or Greater: Pemetrexed + Carboplatin | One Year or Greater: Pemetrexed + Gemcitabine |
|---|---|---|---|---|
| Pericardial effusionCardiac disorders | 0/14 | 0/11 | 0/7 | 1/9 |
| Lower gastrointestinal haemorrhageGastrointestinal disorders | 0/14 | 0/11 | 0/7 | 1/9 |
| Rectal haemorrhageGastrointestinal disorders | 0/14 | 0/11 | 0/7 | 1/9 |
| PneumoniaInfections and infestations | 0/14 | 1/11 | 0/7 | 1/9 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 0/14 | 0/11 | 0/7 | 1/9 |
| Pleural effusionRespiratory, thoracic and mediastinal disorders | 1/14 | 0/11 | 0/7 | 1/9 |
| Febrile neutropeniaBlood and lymphatic system disorders | 0/14 | 1/11 | 0/7 | 0/9 |
| Atrial fibrillationCardiac disorders | 0/14 | 1/11 | 0/7 | 0/9 |
| FatigueGeneral disorders | 0/14 | 1/11 | 0/7 | 0/9 |
| Bronchopulmonary aspergillosisInfections and infestations | 0/14 | 1/11 | 0/7 | 0/9 |
| Event | Less Than One Year: Pemetrexed | Less Than One Year: Pemetrexed + Gemcitabine | One Year or Greater: Pemetrexed + Carboplatin | One Year or Greater: Pemetrexed + Gemcitabine |
|---|---|---|---|---|
| FatigueGeneral disorders | 11/14 | 11/11 | 5/7 | 6/9 |
| AnaemiaBlood and lymphatic system disorders | 6/14 | 10/11 | 1/7 | 3/9 |
| HypertensionVascular disorders | 5/14 | 6/11 | 5/7 | 5/9 |
| NauseaGastrointestinal disorders | 9/14 | 6/11 | 3/7 | 6/9 |
| CoughRespiratory, thoracic and mediastinal disorders | 5/14 | 4/11 | 4/7 | 2/9 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 8/14 | 6/11 | 4/7 | 3/9 |
| ConstipationGastrointestinal disorders | 6/14 | 6/11 | 3/7 | 3/9 |
| DepressionPsychiatric disorders | 2/14 | 6/11 | 1/7 | 2/9 |
| Gastrooesophageal reflux diseaseGastrointestinal disorders | 7/14 | 1/11 | 0/7 | 1/9 |
| PyrexiaGeneral disorders | 3/14 | 5/11 | 0/7 | 2/9 |
| Age, Customized(participants) | Less Than One Year: Pemetrexed | Less Than One Year: Pemetrexed + Gemcitabine | One Year or Greater: Pemetrexed + Carboplatin | One Year or Greater: Pemetrexed + Gemcitabine | Total |
|---|---|---|---|---|---|
| <=65 years | 6 | 3 | 2 | 4 | 15 |
| >65 years | 8 | 8 | 5 | 5 | 26 |
| Sex: Female, Male(Participants) | Less Than One Year: Pemetrexed | Less Than One Year: Pemetrexed + Gemcitabine | One Year or Greater: Pemetrexed + Carboplatin | One Year or Greater: Pemetrexed + Gemcitabine | Total |
|---|---|---|---|---|---|
| Female | 6 | 6 | 0 | 4 | 16 |
| Male | 8 | 5 | 7 | 5 | 25 |
| Region of Enrollment(participants) | Less Than One Year: Pemetrexed | Less Than One Year: Pemetrexed + Gemcitabine | One Year or Greater: Pemetrexed + Carboplatin | One Year or Greater: Pemetrexed + Gemcitabine | Total |
|---|---|---|---|---|---|
| United States | 14 | 11 | 7 | 9 | 41 |
| Disease Stage at Initial Diagnosis(participants) | Less Than One Year: Pemetrexed | Less Than One Year: Pemetrexed + Gemcitabine | One Year or Greater: Pemetrexed + Carboplatin | One Year or Greater: Pemetrexed + Gemcitabine | Total |
|---|---|---|---|---|---|
| Stage IV | 14 | 11 | 7 | 9 | 41 |
| Eastern Cooperative Oncology Group Performance Status(participants) | Less Than One Year: Pemetrexed | Less Than One Year: Pemetrexed + Gemcitabine | One Year or Greater: Pemetrexed + Carboplatin | One Year or Greater: Pemetrexed + Gemcitabine | Total |
|---|---|---|---|---|---|
| 0 - Fully Active | 6 | 3 | 2 | 6 | 17 |
| 1 - Ambulatory, Restricted Strenuous Activity | 8 | 8 | 5 | 3 | 24 |
| History of Brain Metastates(participants) | Less Than One Year: Pemetrexed | Less Than One Year: Pemetrexed + Gemcitabine | One Year or Greater: Pemetrexed + Carboplatin | One Year or Greater: Pemetrexed + Gemcitabine | Total |
|---|---|---|---|---|---|
| No | 12 | 11 | 7 | 9 | 39 |
| Yes | 2 | 0 | 0 | 0 | 2 |
| Prior Systemic Therapy(participants) | Less Than One Year: Pemetrexed | Less Than One Year: Pemetrexed + Gemcitabine | One Year or Greater: Pemetrexed + Carboplatin | One Year or Greater: Pemetrexed + Gemcitabine | Total |
|---|---|---|---|---|---|
| Adjuvant | 12 | 11 | 6 | 9 | 38 |
| Neoadjuvant | 3 | 0 | 1 | 1 | 5 |
| Race/Ethnicity(participants) | Less Than One Year: Pemetrexed | Less Than One Year: Pemetrexed + Gemcitabine | One Year or Greater: Pemetrexed + Carboplatin | One Year or Greater: Pemetrexed + Gemcitabine | Total |
|---|---|---|---|---|---|
| Black or African American | 0 | 0 | 2 | 0 | 2 |
| East Asian | 0 | 0 | 0 | 1 | 1 |
| West Asian | 0 | 0 | 0 | 1 | 1 |
| Caucasian | 14 | 11 | 5 | 7 | 37 |
The record gives a start of Sep 2006, a primary completion of Jun 2008 and a completion of Apr 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Jul 2009, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Aug 2010. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Pemetrexed · Gemcitabine · Carboplatin